

Antibiogram Data from 2025 Isolates

Niaz Banaei, M.D., Director of Clinical Microbiology Laboratory
William Rotunno, CLS, Laboratory Reference Technologist, Antibiotics
Farnaz Foroughi, CLS, Laboratory Reference Technologist, AFB
Laleh Ghafghaichi, CLS, Laboratory Reference Technologist, Mycology

Values expressed are % susceptible R = intrinsic resistance "-" = data not available

Gram Negative Rods	No. of Isolates (a)	Penicillins		Cephalosporins and Lactams						Carbapenems		Aminoglyc's			Others		Urines Only
		Ampicillin (\$)	Piper/Tazobactam (b)(\$\$)	Cefazolin (\$)	Cefuroxime (IV) (\$)	Ceftriaxone (\$)	Ceftazidime (\$)	Cefepime (b) (\$)	Aztreonam (\$\$\$)	Ertapenem (\$\$\$)	Meropenem (\$\$)	Amikacin (\$\$\$)	Gentamicin (\$\$\$)	Tobramycin (\$\$\$)	Ciprofloxacin (\$)	Trimethoprim/sulfa (\$)	Nitrofurantoin (c) (\$\$\$)
<i>Achromobacter xylosoxidans</i>	20(d,e)	R	90	R	R	R	85	10	10	R	95	20	5	5	25	95	-
<i>Acinetobacter baumannii</i> complex	16(d)	R	-	R	R	R	100	100	R	R	100	100	100	100	100	100	-
<i>Citrobacter freundii</i> complex	14(d)	R	64 / 7	R	R	64	64	100 / 0	33	100	100	-	93	-	93	86	100
<i>Enterobacter cloacae</i> complex	68	R	65 / 0	R	R	45	58	82 / 13	62	62	100	-	98	100	95	92	46
<i>Escherichia coli</i>	550	42	94 / 1	79	64	84	87	87 / 1	70	99	100	91	87	75	62	66	98
<i>Klebsiella aerogenes</i>	19(d)	R	84 / 0	R	R	79	79	100 / 0	67	95	100	-	100	100	90	100	20
<i>Klebsiella oxytoca</i>	36	R	94 / 3	50	92	89	89	89 / 0	92	100	100	-	89	93	89	78	90
<i>Klebsiella pneumoniae</i>	115	R	86 / 6	79	83	83	84	83 / 1	83	93	94	88	89	81	75	78	9
<i>Morganella morganii</i>	18(d,e)	R	94 / 0	R	R	86	77	-	-	100	100	-	78	71	67	67	R
<i>Proteus mirabilis</i>	43	86	100 / 0	88	-	95	95	100 / 0	-	100	100	-	93	-	95	84	R
<i>Pseudomonas aeruginosa</i>	152	R	92	R	C/T	98	95	93	84	R	92	-	-	-	82	R	R
<i>Pseudomonas aeruginosa</i> (CF-mucoid) (f)	19(d)	R	84	R	C/T	100	84	79	79	Imp 84	95	-	-	74	68	R	R
<i>Pseudomonas aeruginosa</i> (CF-non-mucoid) (f)	45	R	87	R	C/T	98	93	91	80	Imp 82	91	-	-	78	84	R	R
<i>Salmonella</i> spp.	30	93	-	R	R	100	-	-	-	-	-	R	R	R	33	93	-
<i>Serratia marcescens</i>	38	R	100 / 0	R	R	92	100	100 / 0	100	100	100	-	100	65	90	100	R
<i>Stenotrophomonas maltophilia</i>	53	R	R	R	R	-	-	-	R	R	R	R	R	Levo	100	98	-

(a) First isolate from each patient was included.
 (b) Shows susceptible / susceptible-dose dependent.
 (c) Urine only.
 (d) Data from isolate totals <30 may be statistically unreliable.
 (e) Includes isolates from 2024.
 (f) Cystic fibrosis patient isolates tested by disk diffusion.

C/T = Ceftolozane/Tazobactam;
 Imp = Imipenem; Levo = Levofloxacin

Values expressed are % susceptible R = intrinsic resistance "-" = data not available"

Gram Positive Cocci

	Number of Isolates (a)	Beta-Lactams							Others										
		Oxacillin/Nafcillin (\$)		Penicillin or Ampicillin (\$)			1st Generation cephem (\$)	Cefuroxime (\$)	Ceftriaxone (\$)	Meropenem (\$)	Levofloxacin (\$)	Ciprofloxacin (b) (\$)	Clindamycin (c) (\$)	Erythromycin (\$\$\$)	Nitrofurantoin (b) (\$\$\$)	Trimethoprim/sulfa (\$)	Vancomycin (\$\$\$)	Tetracycline (\$\$)	Linezolid (\$\$\$\$)
		%S	%I	%R															
Staphylococcus aureus	558	87	(d)	-	-	87	-	-	-	-	-	76	68	-	100	100	-	-	
MRSA only	69	0	0	-	-	0	-	-	-	-	-	59	32	-	97	100	87	99	
Staphylococcus lugdunensis	5(e,f)	60	(d)	-	-	60	-	-	-	-	-	60	80	-	100	100	-	-	
Staphylococcus spp., Coagulase-negative	49	44	(d)	-	-	44	-	-	-	-	-	56	35	-	83	100	-	-	
Enterococcus faecium	20(e,f)	-	50	-	50	R	R	R	-	-	50	R	-	36	R	100	-	95	
Enterococcus faecalis	27(e)	-	100	-	0	R	R	R	-	-	-	R	-	-	R	100	-	-	
Streptococcus group B	31	-	100	0	0	-	-	-	-	-	-	55	-	-	-	-	-	-	
Viridans group Streptococci	39	-	74	26	0	-	-	97	-	76	-	87	65	-	-	100	-	-	
Streptococcus pneumoniae	27(e)	-	70(g)	-	30	-	83	96(g)	78	-	-	90	59	-	74	100	Doxycycline	60	

Drug cost: Please choose the appropriate antibiotic based on best spectrum of coverage and lowest cost. Costs are reflective of 1 day of therapy based on adult dosing and include drug levels and reformulations.

\$ = \$0-20
 \$\$ = \$20-50
 \$\$\$ = \$50-100
 \$\$\$\$ = >\$100

(a) First isolate from each patient was included. (b) Urine only. (c) Testing for inducible clindamycin resistance performed on all Staphylococci, group B Strep, and S. pneumoniae. (d) Penicillin sensitivity confirmed by request. (e) Data from isolate totals <30 may be statistically unreliable. (f) Includes isolates from 2024. (g) Based on meningitis interpretive criteria (more conservative). Nonmeningitis penicillin interpretation is 100%.

Candida

Percent Susceptible By Broth Microdilution (YeastOne, Trek Diagnostics)	No. Tested	Amphotericin B (a) (\$\$\$\$)	Fluconazole (b) (\$)	Voriconazole (\$\$\$\$)	Caspofungin (\$\$\$)
Candida albicans	23(c,d)	100	96/4	96	96
Candida glabrata	6(c,d)	100	0/83	-	100
Candida parapsilosis	12(c,d)	100	100/0	100	100
Other Candida species	5(c,d)	100	(e)	40	100

(a) Suggested Ampho Resistant breakpoint MIC > or = 2 mcg/ml. (b) Shows susceptible / susceptible-dose dependent. (c) Data from isolate totals <30 may be statistically unreliable. (d) Includes isolates from 2024. (e) C. krusei is intrinsically resistant to fluconazole.

Haemophilus influenzae

For infections with beta-lactamase producing H. influenzae: cefuroxime, ceftriaxone, trimethoprim/sulfamethoxazole, amoxicillin/clavulanate, or azithromycin is recommended. Ceftriaxone is drug of choice for CNS infections. At LPCH, 76% (n=41) of H. influenzae are ampicillin susceptible.